Navigation Links
FDA Approves LUSEDRA(TM) (fospropofol disodium) Injection for Monitored Anesthesia Care (MAC) Sedation

WOODCLIFF LAKE, N.J., Dec. 14 /PRNewswire/ -- Eisai Corporation of North America today announced that the U.S. Food and Drug Administration (FDA) has approved LUSEDRA(TM) (fospropofol disodium) Injection, an intravenous sedative-hypnotic agent for monitored anesthesia care (MAC) sedation in adult patients undergoing diagnostic or therapeutic procedures.

In the approval, the FDA required that LUSEDRA be used only by persons trained in the administration of general anesthesia and that all patients should be continuously monitored by persons not involved in the conduct of the procedure.

On May 7, 2008, the FDA Advisory Committee on Anesthetic and Life Support Drugs voted 6 to 3 in favor (with one abstention) of approval of LUSEDRA for use as an intravenous sedative-hypnotic agent for sedation in adult patients undergoing diagnostic or therapeutic procedures. The committee recommended use of LUSEDRA by healthcare providers who are appropriately trained.

"We are pleased with the FDA's decision to approve Lusedra, as it provides a new option for monitored anesthesia care (MAC) sedation in adult patients," said Cynthia Schwalm, President, Eisai Inc. "With the approval of Lusedra, Eisai continues to fulfill its human health care mission to address the unmet needs of patients."

The FDA has recommended that LUSEDRA be classified as a controlled substance. A final scheduling decision is expected from the U.S. Drug Enforcement Administration (DEA) after publishing a proposed rule in the Federal Register and allowing for public comment. Once LUSEDRA receives final scheduling designation, the label will be amended.

About LUSEDRA(TM) (fospropofol disodium) Injection

LUSEDRA(TM) (fospropofol disodium) Injection is a proprietary water-soluble prodrug of propofol that, after intravenous injection, is converted by alkaline phosphatase enzymes in the body into propofol. LUSEDRA is an intravenous sedative-hypnotic agent indicated for monitored anesthesia care (MAC) sedation in adult patients undergoing diagnostic or therapeutic procedures.

Important Safety Information

LUSEDRA should be administered only by persons trained in the administration of general anesthesia and not involved in the conduct of the diagnostic or therapeutic procedure. Patients should be continuously monitored during sedation and through the recovery process for early signs of hypotension, apnea, airway obstruction, and/or oxygen desaturation. Facilities for providing cardiopulmonary resuscitation must be immediately available.

The following serious adverse reactions have been reported with the use of LUSEDRA.

    -- Hypotension
       -- Hypotension was reported in 18/455 (4%) patients treated with
          LUSEDRA using the standard or modified dosing regimen.
       -- Patients with compromised myocardial function, reduced vascular
          tone, or who have reduced intravascular volume may be at an
          increased risk for hypotension.

    -- Hypoxemia
       -- Hypoxemia was reported in 20/455 (4%) patients treated with LUSEDRA
          using the standard or modified dosing regimen. Retention of
          purposeful responsiveness did not prevent patients from becoming
          hypoxemic following administration of LUSEDRA.

    -- Respiratory depression
       -- Apnea was reported in 1/455 (< 1%) patients treated with LUSEDRA
          using the standard or modified dosing regimen.

    -- Loss of purposeful responsiveness
       -- LUSEDRA has not been studied for use in general anesthesia. However,
          administration of LUSEDRA may inadvertently cause patients to become
          unresponsive or minimally responsive to vigorous tactile or painful
          stimulation. The incidence of patients who became minimally
          responsive or unresponsive to vigorous tactile or painful
          stimulation was 7/183 (4%) for colonoscopy and 24/149 (16%) for
          bronchoscopy. The duration of minimal or complete unresponsiveness
          ranged from 2 to 16 minutes in colonoscopy patients and from 2 to 20
          minutes in bronchoscopy patients.

The use of supplemental oxygen is recommended in all patients receiving LUSEDRA. Airway assistance maneuvers may be required. As with other sedative-hypnotic agents, LUSEDRA may produce additive cardio-respiratory effects when administered with other cardio-respiratory depressants such as benzodiazepines and narcotic analgesics. When LUSEDRA is used at greater than the recommended doses, the incidence of serious adverse reactions is increased.

The most common adverse reactions (reported in greater than 20%) are paresthesia and pruritis.

    Please see FDA-approved labeling text at .

About Eisai Corporation of North America

Eisai Corporation of North America is a wholly-owned subsidiary of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: neurology, gastrointestinal disorders and oncology/critical care.

Eisai Corporation of North America supports the activities of its operating companies in North America, which include: Eisai Research Institute of Boston, Inc., a discovery operation with strong organic chemistry capabilities; Morphotek, Inc., a biopharmaceutical company specializing in the development of therapeutic monoclonal antibodies; Eisai Medical Research Inc., a clinical development group; Eisai Inc., a commercial operation with manufacturing and marketing/sales functions; and Eisai Machinery U.S.A., which markets and maintains pharmaceutical manufacturing machinery. For more information about Eisai, please visit

About Eisai Inc.

Eisai Inc. is a U.S. pharmaceutical subsidiary of Eisai Co., Ltd. that was established in 1995 and is ranked among the top-20 U.S. pharmaceutical companies (based on retail sales). Eisai Inc. began marketing its first product in the United States in 1997 and has rapidly grown to become an integrated pharmaceutical business with fiscal year 2007 (year ended March 31, 2008) sales of approximately $3 billion, including the results of the acquisition of MGI PHARMA, Inc.

Eisai Inc. employs approximately 1,900 people at its headquarters in Woodcliff Lake, NJ, at its state-of-the-art pharmaceutical production and formulation research and development facility in Research Triangle Park, NC,

and in the field. For more information about Eisai, please visit

SOURCE Eisai Corporation of North America
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain
2. FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder
3. FDA Approves Rapid-Acting Insulin Apidra(R) for Treatment of Children with Diabetes
4. FDA Approves Bayer HealthCares Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A
5. F.D.A. Approves SANCUSO(R), the First and Only Patch for Preventing Nausea and Vomiting in Cancer Patients Undergoing Chemotherapy
6. FDA Approves First Hepatitis B Viral Load Test
7. U.S. FDA Approves Requip(R) XL(TM), the First and Only Oral Once-Daily Non-Ergot Dopamine Agonist for Parkinsons Disease
8. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
9. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
10. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
11. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
Post Your Comments:
(Date:10/12/2015)... 2015 About epilepsy --> ... of brain disorders manifested by benign to severe, disabling, ... from brain malformations and tumors to meningitis, high-risk pregnancies, ... the disease is unidentified, as is witnessed in the ... An imbalance between the inhibitory and excitatory signals of ...
(Date:10/12/2015)... Elbit Imaging Ltd. ("EI" or the ... board of directors approved a program to repurchase up to ... H Notes and Series I Notes, which are traded on ... the Company will have a significant preference to the purchase ... to time in the open market on the Tel Aviv ...
(Date:10/12/2015)... 2015 A new computer program that analyzes ... whether they will develop effective language skills within two ... in the journal Brain and Behavior . ... the journal,s Oct. 12 online edition, researchers at Cincinnati ... how specific regions of the brain respond to auditory ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... October 13, 2015 , ... Doulagivers is O'Brien's licensed ... and End of Life Doula Training. A Doulagiver is a non-medical person ... emotionally. Based on her #1 International bestselling book Creating Positive Passings & ...
(Date:10/12/2015)... ... October 13, 2015 , ... North American Tool Corporation ... the 2015 IBC National Meeting in Rosemont, IL on October 4th. ... and standards of excellence that customers have come to expect from members of IBC’s ...
(Date:10/12/2015)... CA (PRWEB) , ... October 12, 2015 , ... ... on August 19, 2015, high school aged female athletes, particularly in the ... potentially sidelining repetitive motion and mechanical overuse injuries than male peers in the ...
(Date:10/12/2015)... ... October 12, 2015 , ... ... hypnosis by individuals who lack professional education and clinical training in a health ... for a variety of purposes such as: losing weight, managing pain, or stopping ...
(Date:10/12/2015)... ... ... The Horizon Foundation for New Jersey has awarded $846,600 in grants to ... quality of life in the Garden State. The grants, representing the second round of ... charitable arm of Horizon Blue Cross Blue Shield of New Jersey, the Horizon Foundation ...
Breaking Medicine News(10 mins):